Solventum Completes Acquisition of Acera Surgical
PRNewswire (Tue, 23-Dec 4:05 PM ET)
Stock futures marginally higher as Wall Street looks towards a Santa Claus rally
Seeking Alpha News (Tue, 23-Dec 7:02 AM ET)
Solventum is the top performing healthcare supplies stock YTD
Seeking Alpha News (Mon, 22-Dec 1:07 PM ET)
PRNewswire (Wed, 17-Dec 4:05 PM ET)
PRNewswire (Tue, 16-Dec 4:05 PM ET)
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
PRNewswire (Tue, 25-Nov 4:05 PM ET)
Solventum Announces Agreement to Acquire Acera Surgical
PRNewswire (Thu, 20-Nov 9:01 AM ET)
Solventum Announces $1 Billion Share Repurchase Program
PRNewswire (Thu, 20-Nov 9:00 AM ET)
Solventum Reports Third Quarter 2025 Financial Results
PRNewswire (Thu, 6-Nov 4:06 PM ET)
Solventum to Participate in the 2025 Stifel Healthcare Conference
PRNewswire (Mon, 3-Nov 4:08 PM ET)
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Solventum trades on the NYSE stock market under the symbol SOLV.
As of December 26, 2025, SOLV stock price climbed to $80.46 with 481,824 million shares trading.
SOLV has a beta of 0.85, meaning it tends to be less sensitive to market movements. SOLV has a correlation of 0.28 to the broad based SPY ETF.
SOLV has a market cap of $13.95 billion. This is considered a Large Cap stock.
Last quarter Solventum reported $2 billion in Revenue and $1.50 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.07.
The top ETF exchange traded funds that SOLV belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.
SOLV has outperformed the market in the last year with a return of +20.9%, while the SPY ETF gained +16.0%. In the last 3 month period, SOLV beat the market returning +12.0%, while SPY returned +4.7%. However, in the most recent 2 weeks SOLV has underperformed the stock market by returning -1.8%, while SPY returned +0.7%.
SOLV support price is $78.91 and resistance is $81.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SOLV shares will trade within this expected range on the day.
